secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-09-17T21:05:24+00:00
Accession:  0001193125-26-394492
Event type: m_and_a
Sentiment:  positive
Materiality: 0.72
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest secures exclusive option to license Senlang's CD7-targeted in vivo CAR-T platform
--------------------------------------------------------------------------------

- Option exercisable within 4 months for ~$447,000 fee; exclusive license for ex-Greater China rights.
- Post-exercise fees: annual maintenance $10M-$14M over first 3 years, 6% net-sales royalty, sublicense revenue share.
- Lead BCMA/GPRC5D dual-targeting candidate in Phase 1 for relapsed/refractory multiple myeloma; early in vivo CAR-T generation observed.
- As of Aug 25, 2026, no Grade 3+ CRS or ICANS; safety profile supports continued dose escalation.
- Agreement complements Tempest's existing LNP platform; expands portfolio to hematologic and autoimmune indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/0001193125-26-394492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/d185404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-394492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer